重藥控股(000950.SZ)業績快報:上半年淨利降35.31%至3億元
格隆匯8月2日丨重藥控股(000950.SZ)披露2020年半年度業績快報,報告期內,公司實現營業總收入17.07億元,同比增長5.30%;營業利潤4.30億元,同比下降32.07%;利潤總額4.31億元,同比下降31.18%;歸屬於上市公司股東的淨利潤3.00億元,同比下降35.31%;基本每股收益0.17元。
報告期內,營業利潤、利潤總額、歸屬於上市公司股東的淨利潤以及每股收益降幅均超過30%。主要原因:受新型冠狀病毒感染肺炎疫情影響,醫療門診機構經營情況未完全恢復正常等原因,2020年上半年公司主營業務增長有所放緩,應收賬款和存貨都顯著增長,應收賬款回款減慢,導致信用減值損失同比增加,帶息負債增加帶來財務費用同比增加,對利潤影響較大,利潤較上年同期明顯下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.